[ CAS No. 132684-59-4 ] {[proInfo.proName]}

Name: 132684-59-4|Fmoc-HoPhe-OH|97%
Brand: Ambeed
SKU: A244629
Price: 10.0 USD
Availability: InStock
Rating: 99 (22 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 132684-59-4 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 132684-59-4 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 132684-59-4 ]

SDS Specification

Alternatived Products of [ 132684-59-4 ]

Product Details of [ 132684-59-4 ]

CAS No. :	132684-59-4	MDL No. :	MFCD00077046
Formula :	C₂₅H₂₃NO₄	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	CIHPCIUGLIZADU-QHCPKHFHSA-N
M.W :	401.45	Pubchem ID :	2761467
Synonyms :

Calculated chemistry of [ 132684-59-4 ]

Physicochemical Properties

Num. heavy atoms :	30
Num. arom. heavy atoms :	18
Fraction Csp3 :	0.2
Num. rotatable bonds :	9
Num. H-bond acceptors :	4.0
Num. H-bond donors :	2.0
Molar Refractivity :	114.47
TPSA :	75.63 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	Yes
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	Yes
CYP2D6 inhibitor :	Yes
CYP3A4 inhibitor :	Yes
Log Kp (skin permeation) :	-5.2 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.73
Log Po/w (XLOGP3) :	5.0
Log Po/w (WLOGP) :	4.61
Log Po/w (MLOGP) :	3.63
Log Po/w (SILICOS-IT) :	4.44
Consensus Log Po/w :	4.08

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.56

Water Solubility

Log S (ESOL) :	-5.33
Solubility :	0.00188 mg/ml ; 0.00000469 mol/l
Class :	Moderately soluble
Log S (Ali) :	-6.33
Solubility :	0.000189 mg/ml ; 0.00000047 mol/l
Class :	Poorly soluble
Log S (SILICOS-IT) :	-7.77
Solubility :	0.0000068 mg/ml ; 0.0000000169 mol/l
Class :	Poorly soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	3.0
Synthetic accessibility :	4.01

Safety of [ 132684-59-4 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 132684-59-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 132684-59-4 ]

[ 132684-59-4 ] Synthesis Path-Downstream 1~88

1
[ 20866-48-2 ]
[ 71989-14-5 ]
[ 132684-59-4 ]
(R)-N₅-(tert.-butoxy-carbonyl)-N₂-(9-fluorenylmethoxycarbonyl)-ornithine [ No CAS ]
[ 110116-74-0 ]

Reference： [1]Journal of Medicinal Chemistry,1987,vol. 30,p. 2094 - 2099

2
[ 2627-86-3 ]
[ 132684-59-4 ]
[ 127-17-3 ]
2-[(S)-3-Phenyl-1-((S)-1-phenyl-ethylcarbamoyl)-propylamino]-propionic acid [ No CAS ]

Reference： [1]Journal of the American Chemical Society,1996,vol. 118,p. 10337 - 10338

3
[ 3886-69-9 ]
[ 132684-59-4 ]
[ 127-17-3 ]
2-[(S)-3-Phenyl-1-((R)-1-phenyl-ethylcarbamoyl)-propylamino]-propionic acid [ No CAS ]

Reference： [1]Journal of the American Chemical Society,1996,vol. 118,p. 10337 - 10338

4
[ 132684-59-4 ]
[ 127-17-3 ]
[ 91-00-9 ]
2-[(S)-1-(Benzhydryl-carbamoyl)-3-phenyl-propylamino]-propionic acid [ No CAS ]

Reference： [1]Journal of the American Chemical Society,1996,vol. 118,p. 10337 - 10338

5
[ 688763-60-2 ]
[ 505-54-4 ]
[ 35661-40-6 ]
[ 132684-59-4 ]
(S)-2-((S)-3-Carbamoyl-2-{15-[(S)-1-((S)-1-carbamoyl-2-phenyl-ethylcarbamoyl)-3-phenyl-propylcarbamoyl]-pentadecanoylamino}-propionylamino)-3-phenyl-propionic acid [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 2239 - 2242

6
[ 688763-60-2 ]
[ 505-54-4 ]
[ 71989-23-6 ]
[ 132684-59-4 ]
(S)-2-((S)-3-Carbamoyl-2-{15-[(1S,2S)-1-((S)-1-carbamoyl-3-phenyl-propylcarbamoyl)-2-methyl-butylcarbamoyl]-pentadecanoylamino}-propionylamino)-3-phenyl-propionic acid [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 2239 - 2242

7
N'-[(9H-fluoren-9-ylmethoxy)carbonyl]-1H-imidazole-1-carbohydrazide [ No CAS ]
[ 71989-31-6 ]
[ 35737-15-6 ]
[ 132684-59-4 ]
C₂₇H₃₃N₇O₄ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2005,vol. 13,p. 4408 - 4424

8
N'-[(9H-fluoren-9-ylmethoxy)carbonyl]-1H-imidazole-1-carbohydrazide [ No CAS ]
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-fluorophenyl)propanoic acid [ No CAS ]
[ 115951-16-1 ]
[ 132684-59-4 ]
1-(1-aminocyclohexane-1-carbonyl)-4-[2S-N-[2S-3-(m-fluorophenyl)propan-2-yl-amide]-4-phenylbutan-2-yl-amide]semicarbazide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2005,vol. 13,p. 4408 - 4424

9
Bz-Nle-Lys(Boc)-Arg(Pbf)-OH [ No CAS ]
[ 132684-59-4 ]
Bz-Nle-Lys-Arg-homoPhe-H [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 40 - 43

10
[ 34306-42-8 ]
[ 132684-59-4 ]
(S)-2-Amino-N-((S)-1-carbamoyl-3-phenyl-propyl)-butyramide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 3614 - 3617

11
carbonic acid 3-(4-hydroxy-phenyl)-propyl ester 4-nitro-phenyl ester [ No CAS ]
[ 35737-10-1 ]
[ 132684-59-4 ]
[ 110-58-7 ]
BrCH₂CH(OEt)O-Resin [ No CAS ]
(6S,9aS)-4,7-Dioxo-8-pentyl-6-phenethyl-hexahydro-pyrazino[1,2-a]pyrimidine-1-carboxylic acid 3-(4-hydroxy-phenyl)-propyl ester [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2002,vol. 45,p. 1395 - 1398

12
[ 18523-48-3 ]
[ 71989-14-5 ]
[ 71989-18-9 ]
[ 132684-59-4 ]
Fmoc-Gly-OH [ No CAS ]
Fmoc-Leu-OH [ No CAS ]
C₃₉H₅₃N₁₁O₁₄ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 5590 - 5594

13
[ 18523-48-3 ]
[ 71989-14-5 ]
[ 71989-18-9 ]
[ 132684-59-4 ]
Fmoc-Gly-OH [ No CAS ]
Fmoc-Leu-OH [ No CAS ]
cyclo[GhFDEGLE-(β-(1H-[1,2,3]triazol-4-yl)-L-alanyl)]-NH2 [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 5590 - 5594

14
[ 18523-48-3 ]
[ 71989-14-5 ]
[ 71989-18-9 ]
[ 132684-59-4 ]
Fmoc-Pro-OH [ No CAS ]
Fmoc-Leu-OH [ No CAS ]
C₄₂H₅₇N₁₁O₁₄ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 5590 - 5594

15
[ 18523-48-3 ]
[ 71989-14-5 ]
[ 71989-18-9 ]
[ 132684-59-4 ]
Fmoc-Pro-OH [ No CAS ]
Fmoc-Leu-OH [ No CAS ]
cyclo[GhFDEPLE-(β-(1H-[1,2,3]triazol-4-yl)-L-alanyl)]-NH2 [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 5590 - 5594

16
[ 29022-11-5 ]
[ 35661-60-0 ]
[ 71989-14-5 ]
[ 132684-59-4 ]
L-Glu(All)-NH-Rink amide MBHA resin [ No CAS ]
c[L-homoPhe-L-homoPhe-L-Asp-L-Glu-Gly-L-Leu-L-Glu]-NH₂ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 5135 - 5146

17
[ 35661-60-0 ]
[ 71989-14-5 ]
[ 71989-18-9 ]
[ 132684-59-4 ]
Fmoc-Gly [ No CAS ]
c[L-homoPhe-L-homoPhe-L-Asp-L-Glu-Gly-L-Leu-L-Glu-L-Glu]-NH₂ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 5135 - 5146

18
[ 132684-59-4 ]
(2S)-N-[(2S)-2-aminobutanoyl]-2-amino-4-phenylbutyronitrile [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 3614 - 3617

19
[ 132684-59-4 ]
[(S)-1-((S)-1-Cyano-3-phenyl-propylcarbamoyl)-propyl]-carbamic acid tert-butyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 3614 - 3617

20
[ 132684-59-4 ]
[ 909778-19-4 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 3614 - 3617

21
[ 132684-59-4 ]
[ 839720-25-1 ]

Reference： [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 56 - 70

22
[ 132684-59-4 ]
[ 839720-26-2 ]

Reference： [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 56 - 70

23
[ 132684-59-4 ]
L-N-[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]-α-[(1-oxobutyl)amino]benzenebutanamide tris(trifluoroacetate) [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 56 - 70

24
[ 132684-59-4 ]
[ 839720-24-0 ]

Reference： [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 56 - 70

25
[ 132684-59-4 ]
4-Cyclohexyl-1-[[2-cinnamoylamino]-4-[(1-aminocarbonyl-3-phenyl)propylamino]carbonylaminophenyl]piperazine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Example 10 4-Cyclohexyl-1-[2-cinnamoylamino]-4-[(1-aminocarbonyl-3-phenyl)propylamino]carbonylaminophenyl}piperazine: This compound was prepared by the method of Example 8 using <strong>[132684-59-4]Fmoc-homophenylalanine</strong> in the initial coupling step to give the title compound with M+1 ion at 609.3 and retention time of 25.78 minutes.

Reference： [1]Patent: US2003/45480,2003,A1

26
[ 132684-59-4 ]
[ 500697-77-8 ]

Yield	Reaction Conditions	Operation in experiment
		Example 11 4-Cyclohexyl-1-[2-(4-phenylbutanoyl)amino]-4-[(1-aminocarbonyl-3-phenyl)propylamino]carbonylaminophenyl}piperazine: This compound was prepared by the method of Example 8 using <strong>[132684-59-4]Fmoc-homophenylalanine</strong> in the initial coupling step to give the title compound with M+1 at 625.3 and a retention time of 26 minutes.
		Example 11 4-Cyclohexyl-1-[2-(4-phenylbutanoyl)amino]-4-(1-aminocarbonyl-3-phenyl)propylamino]carbonylaminophenyl}piperazine This compound was prepared by the method of Example 8 using <strong>[132684-59-4]Fmoc-homophenylalanine</strong> in the initial coupling step to give the title compound with M+1 at 625.3 and a retention time of 26 minutes.

Reference： [1]Patent: US2003/45480,2003,A1
[2]Patent: US2003/87832,2003,A1

27
[ 132684-59-4 ]
[ 500697-69-8 ]

Yield	Reaction Conditions	Operation in experiment
		Example 21 [4-(Piperidin-4-yl)carbonyl-1-[[2-(4-phenylbutanoyl) amino]-4-[(1-aminocarbonyl-2-(naphth-2-yl))ethylamino]-carbonylaminophenyl]homopiperazine This compound was prepared by the method of Example 13 using <strong>[132684-59-4]Fmoc-homophenylalanine</strong> in the initial coupling step to give the title compound with M+1 ion at 668.4 and retention time of 22.88 minutes. Examples 22-25 describe the synthesis of sulfonamide compounds in accordance with the compounds of the present invention.

Reference： [1]Patent: US2003/87832,2003,A1

28
HMPB-BHA resin [ No CAS ]
[ 132684-59-4 ]
C₅₀H₄₇N₂O₇Pol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With pyridine; 2,6-Dichlorobenzoyl chloride; In N,N-dimethyl-formamide; at 20℃; for 20h;	HMPB-BHA resin is placed in a peptide synthesis reaction vessel, and swollen by washing with N, N-dimethylformamide (2x). Fmoc-Hphe-OH in N, N- dimethylformamide is added and the resin is mixed at room temperature for 15 minutes. Pyridine and 2,6-dichlorobenzoyl chloride are added and the mixture is gently shaken for 20 hours. The resin is then washed thoroughly with N, N- dimethylformamide (3x), dichloromethane (3x), methanol (3x), dichloromethane (3x), and N, N-dimethylformamide (3x). The remaining hydroxyl groups of the resin are capped by reacting with benzoyl chloride and pyridine in dichloromethane for 2 hours. The substitution level is determined by the quantitative fulvene-piperidine assay.

Reference： [1]Patent: WO2005/23314,2005,A1 .Location in patent: Page/Page column 144

29
C₃₈H₄₃N₂O₆Pol [ No CAS ]
[ 132684-59-4 ]
C₆₃H₆₄N₃O₉Pol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; for 8h;	Fmoc-Hphe-OH, HOBt, and HBTU in N, N-dimethylformamide and diisopropylethylamine are added to the resin and the reaction is allowed to proceed for 8 hours.

Reference： [1]Patent: WO2005/23314,2005,A1 .Location in patent: Page/Page column 126

30
C₃₁H₃₇N₂O₅Pol [ No CAS ]
[ 132684-59-4 ]
C₅₆H₅₈N₃O₈Pol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; for 5h;	Fmoc-Hphe-OH (3.01 g, 7.5 mmol), HOBt (1.15 g, 7.5 mmol), and HBTU (2.84 g, 7.5 mmol) in 50 ml OF N, N-DIMETHYLFORMAMIDE and 2 ml of diisopropylethylamine were added to the resin and the reaction was allowed to proceed for 5 hours.

Reference： [1]Patent: WO2005/23314,2005,A1 .Location in patent: Page/Page column 92

31
C₃₀H₃₅N₄O₃Pol [ No CAS ]
[ 132684-59-4 ]
C₅₅H₅₆N₅O₆Pol [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2008,vol. 51,p. 4881 - 4889

32
C₂₂H₂₁N₂OPolS [ No CAS ]
[ 132684-59-4 ]
C₄₇H₄₂N₃O₄PolS [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2009,vol. 52,p. 126 - 133

33
[ 214852-52-5 ]
[ 35661-60-0 ]
[ 35661-40-6 ]
[ 132684-59-4 ]
[ 135673-97-1 ]
[ 162558-25-0 ]
[ 1186310-45-1 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2009,vol. 17,p. 5229 - 5237

34
[ 214852-52-5 ]
[ 132684-59-4 ]
[ 135112-28-6 ]
[ 162558-25-0 ]
N-(9-fluorenylmethoxycarbonyl)-3-(β-naphthyl)-L-alanine [ No CAS ]
[ 1348154-68-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2009,vol. 17,p. 5229 - 5237

35
[ 71989-18-9 ]
[ 132684-59-4 ]
[ 77284-32-3 ]
[ 135112-28-6 ]
[ 125238-99-5 ]
N-(9-fluorenylmethoxycarbonyl)-3-(β-naphthyl)-L-alanine [ No CAS ]
[ 1349220-85-4 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2009,vol. 17,p. 5229 - 5237

36
[ 132684-59-4 ]
[ 125238-99-5 ]
[ 135673-97-1 ]
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine [ No CAS ]
[ 1186310-46-2 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2009,vol. 17,p. 5229 - 5237

37
H-Gly-2-chlorotrityl resin [ No CAS ]
[ 132684-59-4 ]
Fmoc-D-Tyr(O-tBu)-OH [ No CAS ]
N-(9-fluorenylmethoxycarbonyl)-3-(β-naphthyl)-L-alanine [ No CAS ]
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine [ No CAS ]
C₅₇H₇₂N₈O₁₀S [ No CAS ]

Reference： [1]Organic and Biomolecular Chemistry,2009,vol. 7,p. 3805 - 3809

38
knorr amide resin [ No CAS ]
[ 29022-11-5 ]
[ 68858-20-8 ]
[ 35661-60-0 ]
[ 71989-38-3 ]
[ 71989-26-9 ]
[ 103213-32-7 ]
[ 132388-59-1 ]
[ 132684-59-4 ]
[ 109425-51-6 ]
(2S,4R)-4-tert-butoxy-1-(9H-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid [ No CAS ]
[HFE]NGVCCGYKLCHOC-NH₂; O = L-trans-hydroxyproline; [HFE] = L-homophenylalanine [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2009,vol. 52,p. 6991 - 7002

39
C₂₉H₃₇N₂O₃Pol [ No CAS ]
[ 5292-21-7 ]
[ 29022-11-5 ]
[ 132684-59-4 ]
[ 188970-92-5 ]
C₆₃H₈₃N₈O₁₂Pol [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2010,vol. 49,p. 1492 - 1495

40
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-6-(dimethylamino)hexanoic acid [ No CAS ]
fmoc-Leu-Alko Resin [ No CAS ]
[ 29022-11-5 ]
[ 35661-60-0 ]
[ 71989-31-6 ]
[ 132684-59-4 ]
[ 64-19-7 ]
Ac-PLG-Hof-K(NMe₂)-L; Hof = homophenylalanine [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 853 - 856

41
fmoc-Leu-Alko Resin [ No CAS ]
N-methylpiperazinepropylglycine [ No CAS ]
[ 29022-11-5 ]
[ 35661-60-0 ]
[ 71989-31-6 ]
[ 132684-59-4 ]
[ 64-19-7 ]
Ac-PLG-Hof-Gmp-L; Hof = homophenylalanine; Gmp = N-methylpiperazinepropylglycine [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 853 - 856

42
fmoc-Leu-Alko Resin [ No CAS ]
[ 29022-11-5 ]
[ 35661-60-0 ]
[ 35661-39-3 ]
[ 71989-31-6 ]
[ 132684-59-4 ]
[ 64-19-7 ]
Ac-PLG-Hof-AL; Hof = homophenylalanine [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 853 - 856

43
fmoc-Leu-Alko Resin [ No CAS ]
[ 29022-11-5 ]
[ 35661-60-0 ]
[ 71989-31-6 ]
[ 71989-38-3 ]
[ 132684-59-4 ]
[ 64-19-7 ]
Ac-PLG-Hof-YL; Hof = homophenylalanine [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 853 - 856

44
HMPB-BHA resin [ No CAS ]
[ 98-88-4 ]
[ 132684-59-4 ]
[ 4659-45-4 ]
Fmoc-Hphe-HMPB BHA Resin [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		HMPB-BHA resin (5.00 g, substitution level = 0.80 mmol/g) was placed in a 200 mL Advanced ChemTech reaction vessel and swollen by washing with DMF (3 x 50 mL). A solution of Fmoc-Hphe-OH (4.85 g, 12.1 mmol) in DMF (50.0 mL) was added to the vessel and the mixture shaken for 0.25 hours. Pyridine (1.62 mL, 20.0 mmol) followed by 2,6-dichlorobenzoyl chloride (1.72 mL, 12.0 mmol) in DMF (50.0 mL) were added and the mixture shaken for 8 hours at 22 C. The resin was washed with DMF, CH2Cl2, methanol, CH2Cl2 and DMF (3 x 90 mL each) then treated with DMF (50.0 mL), pyridine (1.62 mL, 20.0 mmol) and benzoyl chloride (1.40 mL, 12.1 mmol) and the vessel shaken for 3 hours. Final washing was then performed with DMF, CH2Cl2, methanol and CH2Cl2 (3 x 50 mL each) and the loading (0.60 mmol/g) determined by fulvene-piperidine assay.

Reference： [1]Patent: WO2007/5491,2007,A1 .Location in patent: Page/Page column 107

45
Fmoc-Leu-HMPB BHA resin [ No CAS ]
[ 132684-59-4 ]
Fmoc-HPhe-L-HMPB-BHA Resin [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Fmoc-Leu-HMPB BHA resin (4.37 g, substitution level = 0.51 mmol/g) was placed in a 200 ml Advanced ChemTech reaction vessel. The resin was swollen by washing with DMF (2 x 50 mL), and the following steps were performed: (Step 1) The Fmoc group was removed upon exposure to a solution of piperidine in DMF (1 :4 v/v, 50 mL) for 0.5 hours. (Step 2) The resin washed with DMF, CH2Cl2, methanol, CH2Cl2 and DMF (3 x 50 mL each). (Step 3) A solution of Fmoc-Hphe-OH (2.68 g, 6.69 mmol), HOBt (1.02 g, 6.69 mmol), HBTU (2.54 g, 6.69 mmol) and Z-Pr2NEt (3.88 mL, 22.3 mmol) in DMF (50.0 mL) was added to the resin and the reaction vessel shaken 4 hours. (Step 4) The resin washed with DMF, CH2Cl2, methanol, CH2Cl2 and DMF (3 x 50 mL each). (Step 5) The coupling reaction was found to be more than 95% complete as assessed by the fulvene-piperidine assay. Steps 1-5 were repeated with Fmoc-NLys(Boc)-OH, Fmoc-Leu-OH and Fmoc-Pro-OH respectively, to complete the sequence PL-NLys(Boc)~Hphe-Leu

Reference： [1]Patent: WO2007/5491,2007,A1 .Location in patent: Page/Page column 164

46
[ 132327-80-1 ]
[ 91000-69-0 ]
[ 132684-59-4 ]
[ 71989-33-8 ]
[ 1355048-64-4 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 1181 - 1188

47
[ 132684-59-4 ]
[ 71989-33-8 ]
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine [ No CAS ]
[ 1428768-33-5 ]

Reference： [1]Journal of Enzyme Inhibition and Medicinal Chemistry,2013,vol. 28,p. 639 - 643

48
[ 35661-40-6 ]
[ 132684-59-4 ]
C₁₉H₂₃N₃O₂ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2013,vol. 56,p. 4953 - 4965

49
2-chlorotrityl chloride polystyrene resin [ No CAS ]
[ 35661-60-0 ]
[ 35661-40-6 ]
[ 132684-59-4 ]
C₄₄H₄₅ClN₃O₃Pol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Chlorotrityl chloride resin (3.2 mmol) and Fmoc-Phe-OH (6.4 mmol) in DCE (30 mL) were stirred. A solution of DIEA (1.2 mL, 6.6 mmol) was added and the system was stirred for 1 hour. The resin was washed DCE, DMF, 2-Propanol and Et20 and allowed to air dry. To the resin in DMF (40 mL) was added 20% piperidine in DMF and heterogeneous mixture was allowed to shake The solution was filtered and the resin was washed by DMF, MeOH and DCM and allowed to air dry to yield Resin 1009. To the resin 1009 (3.2 mmol) was added DCE (40 mL), and Fmoc-Leu-OH (6.2 mmol), DIEA (13.2 mmol), HOBT (6.4mmol), and BOP (6.4 mmol) and the reaction mixture was allowed to shake. The reaction mixture was filtered and the resin was washed DCE, DMF, 2-Propanol, and Et20 and allowed to air dry. To the resin in DMF (40 mL) was added 20% piperidine in DMF, and heterogeneous mixture was allowed to shake. The solution was filtered and the resin was washed by DMF and DCM, and allowed to air dry to yield Resin 1010. To the resin 1010 (3.2 mmol) was added DCE (40 mL), and Fmoc-HFE-OH (2.56g, 6.4 mmol), DIEA (2.3 mL, 13.2 mmol), HOBT (0.86g, 6.4mmol), and BOP (1 .78g, 6.4 mmol) and the reaction mixture was allowed to shake. The reaction mixture was filtered and the resin was washed DCE, DMF, 2-Propanol, and Et20 and allowed to air dry. To the resin in DMF (40 mL) was added 20% piperidine in DMF and heterogeneous mixture was allowed to shake. The solution was filtered and the resin was washed by DMF, MeOH, and DCM and allowed to air dry to yield Resin 1011.

Reference： [1]Patent: WO2014/18807,2014,A1 .Location in patent: Paragraph 00120; 00121; 00122; 00123; 00124

50
2-chlorotrityl chloride polystyrene resin [ No CAS ]
[ 35661-60-0 ]
[ 71989-33-8 ]
[ 132684-59-4 ]
C₄₂H₄₉ClN₃O₄Pol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		General procedure: Chlorotrityl chloride resin (3.2 mmol) and Fmoc-Ser(tBu)-OH (6.4 mmol) in DCE (30 mL) were stirred. A solution of DIEA (6.6 mmol) was added and the system was stirred for 1 hour. The resin was washed DCE, DMF, 2-Propanol and Et20 and allowed to air dry. To the resin in DMF (40 mL) was added 20% piperidine in DMF and heterogeneous mixture was allowed to shake The solution was filtered and the resin was washed by DMF, MeOH and DCM and allowed to air dry to yield Resin 1017.The same procedure was used in the preparation of Resin 1010 to yield Resin 1018. The same procedure was used in the preparation of Resin 1011 to yield Resin 1019.

Reference： [1]Patent: WO2014/18807,2014,A1 .Location in patent: Paragraph 00143; 00144; 00145; 00146

51
[ 132684-59-4 ]
[ 82379-38-2 ]
p-MBHA resin [ No CAS ]
C₁₈H₁₇N₂O₅Pol [ No CAS ]

Reference： [1]Biopolymers,2013,vol. 100,p. 662 - 674

52
C₁₁H₉N₂O₃Pol [ No CAS ]
[ 71989-28-1 ]
[ 132684-59-4 ]
[ 1639394-64-1 ]

Reference： [1]Amino Acids,2014,vol. 46,p. 931 - 943

53
C₁₁H₉N₂O₃Pol [ No CAS ]
[ 132684-59-4 ]
[ 77284-32-3 ]
[ 1639395-19-9 ]

Reference： [1]Amino Acids,2014,vol. 46,p. 931 - 943

54
C₁₁H₉N₂O₃Pol [ No CAS ]
[ 132684-59-4 ]
[ 172525-85-8 ]
[ 1639395-24-6 ]

Reference： [1]Amino Acids,2014,vol. 46,p. 931 - 943

55
[ 35661-39-3 ]
C₁₁H₉N₂O₃Pol [ No CAS ]
[ 132684-59-4 ]
[ 1639394-81-2 ]

Reference： [1]Amino Acids,2014,vol. 46,p. 931 - 943

56
[ 35661-60-0 ]
C₁₁H₉N₂O₃Pol [ No CAS ]
[ 132684-59-4 ]
[ 1639394-91-4 ]

Reference： [1]Amino Acids,2014,vol. 46,p. 931 - 943

57
[ 35661-60-0 ]
[ 71989-31-6 ]
[ 71989-16-7 ]
[ 91000-69-0 ]
[ 132684-59-4 ]
[ 76-05-1 ]
[ 501-52-0 ]
C₄₆H₇₀N₁₄O₈*C₂HF₃O₂ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 6583 - 6593

58
[ 259526-94-8 ]
[ 132684-59-4 ]
C₄₂H₄₃N₃O₅ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Compounds a (1S,3S) and a (1R,3S) (0.50 g, 1.85 mmol)was dissolved in anhydrous DCM (50 ml) than DIPEA (1.9ml, 11.10 mmol) was added and the reaction mixture wasstirred at room temperature for 30 min under Ar atmosphere.Fmoc-Homophe-OH (2.22 g, 5.55 mmol) amino acid andTCFH (1.55 g, 5.55 mmol) coupling reagent was dissolvedin anhydrous DCM (50 ml) and after 30 min preactivation,the solution was poured into the previously prepared solution. The reaction mixture was stirred at room temperaturefor 10h under Ar atmosphere, diluted with DCM (50 ml) andextracted with aqueous sodium hydrogen sulfate (3100 ml,10 m/v%), sodium hydrogen carbonate (2150 ml) and saturated sodium chloride solutions (2100 ml). The obtained organic layer was dried (Na2SO4), filtered, and evaporated todryness. The Fmoc deprotection and intramolecular cyclization was carried out in a one-pot reaction with piperidine/DCM (5 ml, 10 v/v%). After 30 min the reactionmixture was treated with acetic acid (pH = 4) and evaporated in vacuo to dryness.1c (3S,6S,12aS) and 1c (3S,6R,12aS)

Reference： [1]Medicinal Chemistry,2013,vol. 9,p. 494 - 509

59
[ 259526-94-8 ]
[ 132684-59-4 ]
C₂₆H₂₉N₃O₂ [ No CAS ]
C₂₆H₂₉N₃O₂ [ No CAS ]

Reference： [1]Medicinal Chemistry,2013,vol. 9,p. 494 - 509

60
[ 68858-20-8 ]
[ 71989-31-6 ]
[ 71989-33-8 ]
[ 132684-59-4 ]
C₂₃H₃₃N₄O₆Pol [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2014,vol. 53,p. 11778 - 11782
Angew. Chem.,2014,vol. 126,p. 11972 - 11976,5

61
[ 56-45-1 ]
[ 29022-11-5 ]
[ 35661-60-0 ]
C₂₂H₂₆N₂O₃ [ No CAS ]
[ 71989-31-6 ]
[ 91000-69-0 ]
[ 132684-59-4 ]
[ 77284-32-3 ]
[ 109425-56-1 ]
[ 116611-64-4 ]
PyrRPRLSHKGPNlePPhe [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2015,vol. 58,p. 2431 - 2440

62
[ 35661-39-3 ]
[ 71989-31-6 ]
[ 71989-33-8 ]
[ 71989-14-5 ]
[ 103213-32-7 ]
[ 71989-35-0 ]
[ 132684-59-4 ]
P(Hph)ATCDS-NH₂ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2015,vol. 58,p. 577 - 587

63
[ 35661-39-3 ]
[ 71989-31-6 ]
[ 71989-33-8 ]
[ 103213-32-7 ]
[ 71989-35-0 ]
[ 132684-59-4 ]
PSP(Hph)ATC-NH₂ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2015,vol. 58,p. 577 - 587

64
[ 35661-40-6 ]
[ 105047-45-8 ]
[ 132684-59-4 ]
[ 158599-00-9 ]
K-hPhe-F-O [ No CAS ]

Reference： [1]RSC Advances,2015,vol. 5,p. 22674 - 22684

65
[ 35661-40-6 ]
[ 105047-45-8 ]
[ 132684-59-4 ]
[ 158599-00-9 ]
K-F-hPhe-O [ No CAS ]

Reference： [1]RSC Advances,2015,vol. 5,p. 22674 - 22684

66
[ 35661-40-6 ]
[ 132684-59-4 ]
[ 158599-00-9 ]
hPhe-O-F-O [ No CAS ]

Reference： [1]RSC Advances,2015,vol. 5,p. 22674 - 22684

67
[ 35661-40-6 ]
[ 132684-59-4 ]
[ 158599-00-9 ]
F-O-hPhe-O [ No CAS ]

Reference： [1]RSC Advances,2015,vol. 5,p. 22674 - 22684

68
[ 35661-60-0 ]
[ 71989-33-8 ]
[ 132684-59-4 ]
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine [ No CAS ]
L-S-hPhe-R [ No CAS ]

Reference： [1]RSC Advances,2015,vol. 5,p. 22674 - 22684

69
C₁₉H₃₆N₅O₄PolS [ No CAS ]
[ 132684-59-4 ]
C₄₄H₅₇N₆O₇PolS [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With 4-methyl-morpholine; benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃; for 1h;	General procedure: For each amino acid coupling reaction, 4 equivalents of a Na-Fmoc-protected amino acid, 3.8 equivalents of the coupling reagent HBTU and the additive HOBt were used in the presence of 0.4 M NMM/DMF, and the coupling reaction was allowed to proceed at room temperature for 1 h

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2015,vol. 25,p. 3481 - 3487

70
polyethylene glycol polyamide resin [ No CAS ]
[ 132684-59-4 ]
C₂₅H₂₃N₂O₃Pol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With 4-methyl-morpholine; benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃; for 1h;	General procedure: For each amino acid coupling reaction, 4 equivalents of a Na-Fmoc-protected amino acid, 3.8 equivalents of the coupling reagent HBTU and the additive HOBt were used in the presence of 0.4 M NMM/DMF, and the coupling reaction was allowed to proceed at room temperature for 1 h

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2015,vol. 25,p. 3481 - 3487

71
2-chlorotrityl chloride polystyrene resin [ No CAS ]
[ 132684-59-4 ]
C₄₄H₃₅ClNO₄Pol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 25℃; for 1h;	General procedure: Each 2-chlorotrityl chloride resin (100 mg, 1.6 mmol/g) was placed in a 5 mL polypropylene syringe fitted with a polyethylene filter disc. Each resin was washed with CH2Cl2 (2 mL, 1 h), and a solution of the corresponding Fmoc-amino acid 3a-mm (0.16 mmol) and iPr2NEt (109 muL, 0.64 mmol) in CH2Cl2 (2 mL) were then added. Each mixture was agitated for 1 h at 25 C. Solvents and soluble reagents were removed by suction. All resins were subjected to the following washing treatments with CH2Cl2-MeOH-iPr2NEt (17:2:1, 2 mL × 3), DMF (2 mL × 3), and CH2Cl2 (2 mL × 3).

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2015,vol. 25,p. 4872 - 4877

72
[ 35661-60-0 ]
[ 35661-39-3 ]
Boc-His(Trt)-Gly-Asp(tBu)-Gly-OH [ No CAS ]
[ 35661-40-6 ]
[ 71989-14-5 ]
[ 71989-18-9 ]
[ 71989-23-6 ]
[ 71989-26-9 ]
[ 132388-59-1 ]
[ 132327-80-1 ]
[ 132684-59-4 ]
[ 77284-32-3 ]
[ 143824-78-6 ]
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine [ No CAS ]
Fmoc-Thr(Pg)-OH [ No CAS ]
Fmoc-Ser(Pg)-OH [ No CAS ]
C₁₅₇H₂₃₇N₄₁O₄₇ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 3129 - 3139

73
C₂₂H₂₂NO₃Pol [ No CAS ]
[ 132684-59-4 ]
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine [ No CAS ]
C₅₁H₆₁N₆O₈PolS [ No CAS ]

Reference： [1]ChemMedChem,2016,p. 2147 - 2154

74
[ 3235-69-6 ]
Fmoc-phenylalanine-2-chlorotrityl resin [ No CAS ]
[ 35661-60-0 ]
[ 132684-59-4 ]
[ 868540-16-3 ]